Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Embryonic signaling pathways, in particular those mediated by Wnt and TGF-β, are known to play key roles in tumor progression through the induction of epithelial–mesenchymal transition (EMT). Their simultaneous targeting could therefore represent a desirable anticancer strategy. On the basis of recent findings that both Wnt and TGF-β–associated pathways are regulated by Hippo signaling in mammalian cells, we reasoned that targeting the latter would be more effective in inhibiting EMT. In a search for such inhibitors, we identified a small molecule (C19) with remarkable inhibitory activity not only against Hippo, but also against Wnt and TGF-β pathways. C19 inhibited cancer cell migration, proliferation, and resistance to doxorubicin in vitro, and exerted strong antitumor activity in a mouse tumor model. Mechanistically, C19 induced GSK3-β–mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex. Overall, this study identified C19 as a multi-EMT pathway inhibitor with a unique mechanism of action. The findings that both AMPK and Mst/Lats mediate the antitumor activity of C19 shed light on a potential cross-talk between metabolic and organ size control pathways in regulating cancer progression. By simultaneously targeting these two pathways, C19 may represent a new type of agents to suppress cancer progression and/or its recurrence. Mol Cancer Ther; 13(6); 1457–67. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements
Veeman, M. T., Slusarski, D. C., Kaykas, A., Louie, S. H., & Moon, R. T. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00240-9 · Cited by 945 · cited 2×
“The 8xGTIIC-luciferase reporter, which contains 8 TEAD-binding sites 8xGTIIC (31), was used to measure activation of the Hippo pathway, 8xTCF-luciferase STF (34) to measure Wnt signaling and A3Lux (35) for TGF-b reporter activity.”
MethodThe Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628 · cited 1×
“Deregulation of Hippo signaling has been shown to be associatedwith carcinogenesis (23).”
BackgroundMetformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 1×
“AMPK is also a tumor suppressor and its activation using either metformin or AICAR is among the most promising approaches currently in cancer clinical trials (49).”
BackgroundA genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294 · cited 1×
“A very recent study by Camargo and his group has shown that the tumor suppressor LKB1, which is known for its ability to regulate cellular metabolism through AMPK activation, also regulates Hippo signaling (30).”
Background
Cited by
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
“A small molecule, C19, with remarkable inhibitory effects on the Hippo-YAP, Wnt and TGF-β pathways, was demonstrated to attenuate doxorubicin resistance in vitro and in vivo [58].”
BackgroundRomano, G., Santi, L., Bianco, M. R., Giuffrè, M. R., Pettinato, M., Bugarin, C., Garanzini, C., Savarese, L., Leoni, S., Cerrito, M. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7895 · Cited by 66
“Since it has been reported a relationship between GSK3 and TGF-β pathways in tumor progression of different carcinomas [20, 21] and it has been demonstrated the relationship between chemoresistance and TGF-β in colon cancer [17], we investigated how the TGF-β pathway could contribute to the…”
The hippo pathway: A master regulator of liver metabolism, regeneration, and disease
Nguyen‐Lefebvre, A. T., Selzner, N., Wrana, J. L., & Bhat, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002284rr · Cited by 58
Metadata
- Authors
- Basu, D., Lettan, R., Damodaran, K., Strellec, S., Reyes-Mugica, M., & Rebbaa, A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2014-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 1457-1467
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2143697753
- Cited by
- 69
- References
- 6
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0918
- The paper
- Basu, D., Lettan, R., Damodaran, K., Strellec, S., Reyes-Mugica, M., & Rebbaa, A. (2014). Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0918
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.